medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2024, Number 4

<< Back

Salud Mental 2024; 47 (4)

Physical Comorbidity and Healthcare Utilization in People with Schizophrenia: a systematic review

Salvador M, Porras-Segovia A, Lopez-Fernandez O, Baca-García E

Language: Spanish
References: 92
Page: 189-204
PDF size: 307.23 Kb.


ABSTRACT

Introduction. Schizophrenia is a mental health condition that can lead to significant disability and have a major impact on social and occupational functioning. It tends to decrease life expectancy, which could be attributed to a variety of factors, including poor health habits, barriers to healthcare access, and the stigmatization of mental illness. Objective. The main aim of this systematic review is to examine the physical comorbidity of these patients, and their health service utilization. Method. The protocol has been registered with the PROSPERO database (CRD42020139972) and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A search of PubMed/MEDLINE, EMBASE, Scopus, Web of Science, PsycINFO, Cochrane Library, and ProQuest Health Research Premium Collection yielded 317 articles, 57 of which were selected. Results. The mortality rate of people with schizophrenia is often at least twice that of the general population. In addition, these individuals may be susceptible to other physical health conditions that can significantly shorten their lifespan: cardiovascular and respiratory diseases, diabetes mellitus, oncologic diseases, and chronic infections. Complications during hospitalization and prolonged length of stay due to comorbidities may impede their access to essential healthcare. Discussion and conclusion. Enhancing the healthcare system is crucial to providing adequate care for these patients. Adopting positive lifestyle choices, reducing substance dependence, and abstaining from unconventional antipsychotics can bolster their life expectancy. It is therefore crucial to implement intervention strategies while training professionals to detect and manage physical comorbidities associated with this disorder.


REFERENCES

  1. Attar, R., Berg Johansen, M., Valentin, J. B., Aagaard, J., & Jensen, S. E. (2017).Treatment following myocardial infarction in patients with schizophrenia. PloSOne, 12(12), e0189289. https://doi.org/10.1371/journal.pone.0189289

  2. Bailey, E. A., Wirtalla, C., Sharoky, C. E., & Kelz, R. R. (2018). Disparities inoperative outcomes in patients with comorbid mental illness. Surgery, 163(4),667-671. https://doi.org/10.1016/j.surg.2017.09.029

  3. Bauer-Staeb, C., Jörgensen, L., Lewis, G., Dalman, C., Osborn, D. P. J., & Hayes, J. F.(2017). Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in peoplewith severe mental illness: a total population study of Sweden. The Lancet -Psychiatry, 4(9), 685-693. https://doi.org/10.1016/S2215-0366(17)30253-5

  4. Bernardo, M., Rico-Villademoros, F., García-Rizo, C., Rojo, R., & Gómez-Huelgas,R. (2021). Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients:A Systematic Review of Population-Based Studies. Advances in Therapy, 38(5),2491-2512. https://doi.org/10.1007/s12325-021-01689-8

  5. Bitter, I., Czobor, P., Borsi, A., Fehér, L., Nagy, B. Z., Bacskai, M., Rakonczai,P., Hegyi, R., Németh, T., Varga, P., Gimesi-Országh, J., Fadgyas-Freyler,P., Sermon, J., … Takács, P. (2017). Mortality and the relationship ofsomatic comorbidities to mortality in schizophrenia. A nationwide matchedcohortstudy. European psychiatry, 45, 97-103. https://doi.org/10.1016/j.eurpsy.2017.05.022

  6. Bodén, R., Molin, E., Jernberg, T., Kieler, H., Lindahl, B., & Sundström, J. (2015).Higher mortality after myocardial infarction in patients with severe mentalillness: a nationwide cohort study. Journal of Internal Medicine, 277(6), 727-736. https://doi.org/10.1111/joim.12329

  7. Bouza, C., López-Cuadrado, T., & Amate, J. M. (2010a). Hospital admissions dueto physical disease in people with schizophrenia: a national population-basedstudy. General Hospital Psychiatry, 32(2), 156-163. https://doi.org/10.1016/j.genhosppsych.2009.11.014

  8. Bouza, C., López-Cuadrado, T., & Amate, J. M. (2010b). Physical disease inschizophrenia: a population-based analysis in Spain. BMC Public Health, 10,745. https://doi.org/10.1186/1471-2458-10-745

  9. Bradford, D. W., Goulet, J., Hunt, M., Cunningham, N. C., & Hoff, R. (2016). ACohort Study of Mortality in Individuals With and Without SchizophreniaAfter Diagnosis of Lung Cancer. The Journal of Clinical Psychiatry, 77(12),e1626-e1630. https://doi.org/10.4088/JCP.15m10281

  10. Brink, M., Green, A., Bojesen, A. B., Lamberti, J. S., Conwell, Y., & Andersen, K.(2017). Physical Health, Medication, and Healthcare Utilization among 70-Year-Old People with Schizophrenia: A Nationwide Danish Register Study. AmericanJournal of Geriatric Psychiatry, 25(5), 500-509. doi: 10.1016/j.jagp.2016.12.015

  11. Brink, M., Green, A., Bojesen, A. B., Lamberti, J. S., Conwell, Y., & Andersen,K. (2019). Excess medical comorbidity and mortality across the lifespan inschizophrenia: A nationwide Danish register study. Schizophrenia Research,206, 347-354. https://doi.org/10.1016/j.schres.2018.10.020

  12. Carney, C. P., Jones, L., & Woolson, R. F. (2006). Medical comorbidity in womenand men with schizophrenia: a population-based controlled study. Journal ofGeneral Internal Medicine, 21(11), 1133-1137. https://doi.org/10.1111/j.1525-1497.2006.00563.x

  13. Chen, P. H., Tsai, S. Y., Pan, C. H., Chang, H. M., Chen, Y. L., Su, S. S., Chen. C.C., & Kuo, C. J. (2021). Age Effect on Incidence, Physical, and PsychiatricComorbidity for Sudden Cardiac Death in Schizophrenia: Effet de l’âge surl’incidence, la comorbidité physique et psychiatrique de la mort cardiaque subitedans la schizophrénie. Canadian Journal of Psychiatry / Revue Canadienne dePsychiatrie, 66(4), 367-375. https://doi.org/10.1177/0706743720948429

  14. Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, A. V.,Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., Henderson, C., Francois,C., & Wu, E. (2016). The Economic Burden of Schizophrenia in the UnitedStates in 2013. The Journal of Clinical Psychiatry, 77(6), 764-771. https://doi.org/10.4088/JCP.15m10278

  15. Contreras-Shannon, V., Heart, D. L., Paredes, R. M., Navaira, E., Catano, G., Maffi,S. K., & Walss-Bass, C. (2013). Clozapine-induced mitochondria alterationsand inflammation in brain and insulin-responsive cells. PloS One, 8(3), e59012.https://doi.org/10.1371/journal.pone.0059012

  16. Copeland, L. A., Mortensen, E. M., Zeber, J. E., Pugh, M. J., Restrepo, M. I., &Dalack, G. W. (2007). Pulmonary disease among inpatient decedents: Impactof schizophrenia. Progress in Neuro-psychopharmacology & BiologicalPsychiatry, 31(3), 720-726. https://doi.org/10.1016/j.pnpbp.2007.01.008

  17. Copeland, L. A., Zeber, J. E., Rosenheck, R. A., & Miller, A. L. (2006). Unforeseeninpatient mortality among veterans with schizophrenia. Medical Care, 44(2),110-116. https://doi.org/10.1097/01.mlr.0000196973.99080.fb

  18. Correll, C. U., Ng-Mak, D. S., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., &Loebel, A. (2017). Cardiometabolic comorbidities, readmission, and costs inschizophrenia and bipolar disorder: a real-world analysis. Annals of GeneralPsychiatry, 16, 9. https://doi.org/10.1186/s12991-017-0133-7

  19. Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C.,Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., & Tiihonen, J. (2022).Mortality in people with schizophrenia: a systematic review and meta-analysisof relative risk and aggravating or attenuating factors. World Psychiatry, 21(2),248-271. https://doi.org/10.1002/wps.20994

  20. D’Avanzo, B., La Vecchia, C., & Negri, E. (2003). Mortality in long-stay patientsfrom psychiatric hospitals in Italy--results from the Qualyop Project. SocialPsychiatry and Psychiatric Epidemiology, 38(7), 385-389. https://doi.org/10.1007/s00127-003-0646-z

  21. Dalton, S. O., Suppli, N. P., Ewertz, M., Kroman, N., Grassi, L., & Johansen, C. (2018).Impact of schizophrenia and related disorders on mortality from breast cancer:A population-based cohort study in Denmark, 1995-2011. Breast (Edinburgh,Scotland), 40, 170-176. https://doi.org/10.1016/j.breast.2018.06.002

  22. Daumit, G. L., Pronovost, P. J., Anthony, C. B., Guallar, E., Steinwachs, D. M., &Ford, D. E. (2006). Adverse events during medical and surgical hospitalizationsfor persons with schizophrenia. Archives of General Psychiatry, 63(3), 267-272.https://doi.org/10.1001/archpsyc.63.3.267

  23. DE Hert, M., Correll, C. U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I.,Detraux, J., Gautam, S., Möller, H. J., Ndetei, D. M., Newcomer, J. W., Uwakwe,R., & Leucht, S. (2011). Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care. WorldPsychiatry, 10(1), 52-77. https://doi.org/10.1002/j.2051-5545.2011.tb00014.x

  24. Douzenis, A., Seretis, D., Nika, S., Nikolaidou, P., Papadopoulou, A., Rizos, E. N.,Christodoulou, C., Tsopelas, C., Mitchell, D., & Lykouras, L. (2012). Factorsaffecting hospital stay in psychiatric patients: the role of active comorbidity.BMC Health Services Research, 12, 166. https://doi.org/10.1186/1472-6963-12-166

  25. Foley, D. L., Mackinnon, A., Morgan, V. A., Watts, G. F., Castle, D. J., Waterreus,A., & Galletly, C. A. (2016). Common familial risk factors for schizophreniaand diabetes mellitus. The Australian and New Zealand Journal of Psychiatry,50(5), 488-494. https://doi.org/10.1177/0004867415595715

  26. Fond, G., Salas, S., Pauly, V., Baumstarck, K., Bernard, C., Orleans, V., Llorca, P. M.,Lancon, C., Auquier, P., & Boyer, L. (2019). End-of-life care among patientswith schizophrenia and cancer: a population-based cohort study from the Frenchnational hospital database. The Lancet - Public Health, 4(11), e583-e591.https://doi.org/10.1016/S2468-2667(19)30187-2

  27. Gabilondo, A., Alonso-Moran, E., Nuño-Solinis, R., Orueta, J. F., & Iruin, A.(2017). Comorbidities with chronic physical conditions and gender profilesof illness in schizophrenia. Results from PREST, a new health dataset.Journal of Psychosomatic Research, 93, 102-109. https://doi.org/10.1016/j.jpsychores.2016.12.011

  28. Goldman, L. S. (1999). Medical illness in patients with schizophrenia. The Journal ofClinical Psychiatry, 60(Suppl 21), 10-15.

  29. Goueslard, K., Petit, J. M., Cottenet, J., Chauvet-Gelinier, J. C., Jollant, F., &Quantin, C. (2018). Increased Risk of Rehospitalization for Acute DiabetesComplications and Suicide Attempts in Patients with Type 1 Diabetes andComorbid Schizophrenia. Diabetes Care, 41(11), 2316-2321. https://doi.org/10.2337/dc18-0657

  30. Guadalajara, H., Lopez-Fernandez, O, León Arellano, M., Domínguez-Prieto, V.,Caramés, C., & Garcia-Olmo, D. (2022). The Role of Shared Decision-Makingin Personalised Medicine: Opening the Debate. Pharmaceuticals, 15(2), 215.https://doi.org/10.3390/ph15020215

  31. Gur, S., Weizman, S., Stubbs, B., Matalon, A., Meyerovitch, J., Hermesh, H., &Krivoy, A. (2018). Mortality, morbidity and medical resources utilization ofpatients with schizophrenia: A case-control community-based study. PsychiatryResearch, 260, 177-181. https://doi.org/10.1016/j.psychres.2017.11.042

  32. Gyllensten, A. L., Ovesson, M. N., Hedlund, L., Ambrus, L., & Tornberg, Å.(2020). To increase physical activity in sedentary patients with affective - orschizophrenia spectrum disorders - a clinical study of adjuvant physical therapyin mental health. Nordic Journal of Psychiatry, 74(1), 73-82. https://doi.org/10.1080/08039488.2019.1669706

  33. Hauck, T. S., Liu, N., Wijeysundera, H. C., & Kurdyak, P. (2020). Mortalityand Revascularization among Myocardial Infarction Patients withSchizophrenia: A Population-Based Cohort Study. Canadian Journal ofPsychiatry / Revue Canadienne de Psychiatrie, 65(7), 454-462. https://doi.org/10.1177/0706743720904845

  34. Hayes, J. F., Marston, L., Walters, K., King, M. B., & Osborn, D. P. J. (2017).Mortality gap for people with bipolar disorder and schizophrenia: UK-basedcohort study 2000-2014. The British Journal of Psychiatry: The Journal ofMental Science, 211(3), 175-181. https://doi.org/10.1192/bjp.bp.117.202606

  35. Heiberg, I. H., Jacobsen, B. K., Balteskard, L., Bramness, J. G., Naess, Ø., Ystrom,E., Reichborn-Kjennerud, T., Hultman, C. M., Nesvåg, R., & Høye, A. (2019).Undiagnosed cardiovascular disease prior to cardiovascular death in individualswith severe mental illness. Acta Psychiatrica Scandinavica, 139(6), 558-571.https://doi.org/10.1111/acps.13017

  36. Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years ofpotential life lost and life expectancy in schizophrenia: a systematic review andmeta-analysis. The Lancet - Psychiatry, 4(4), 295-301. https://doi.org/10.1016/S2215-0366(17)30078-0

  37. Hou, P. Y., Hung, G. C., Jhong, J. R., Tsai, S. Y., Chen, C. C., & Kuo, C. J. (2015).Risk factors for sudden cardiac death among patients with schizophrenia.Schizophrenia Research, 168(1-2), 395-401. https://doi.org/10.1016/j.schres.2015.07.015

  38. Huang, C. J., Hsieh, H. M., Tu, H. P., Jiang, H. J., Wang, P. W., & Lin, C. H.(2018). Schizophrenia in type 2 diabetes mellitus: Prevalence and clinicalcharacteristics. European Psychiatry, 54, 102-108. https://doi.org/10.1016/j.eurpsy.2018.08.002

  39. Hughes, J. R. (1993). Possible effects of smoke-free inpatient units on psychiatricdiagnosis and treatment. The Journal of Clinical Psychiatry, 54(3), 109-114.

  40. Ishikawa, H., Yasunaga, H., Matsui, H., Fushimi, K., & Kawakami, N. (2016).Differences in cancer stage, treatment and in-hospital mortality between patientswith and without schizophrenia: retrospective matched-pair cohort study. TheBritish Journal of Psychiatry: The Journal of Mental Science, 208(3), 239-244.https://doi.org/10.1192/bjp.bp.114.156265

  41. Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., & Lacro, J. P. (1996). Medicalcomorbidity in schizophrenia. Schizophrenia Bulletin, 22(3), 413-430. https://doi.org/10.1093/schbul/22.3.413

  42. Jørgensen, M., Mainz, J., Lange, P., & Paaske Johnsen, S. (2018). Quality of careand clinical outcomes of chronic obstructive pulmonary disease in patients withschizophrenia. A Danish nationwide study. International Journal for Quality inHealth Care, 30(5), 351-357. https://doi.org/10.1093/intqhc/mzy014

  43. Kisely, S., Forsyth, S., & Lawrence, D. (2016). Why do psychiatric patients havehigher cancer mortality rates when cancer incidence is the same or lower? TheAustralian and New Zealand Journal of Psychiatry, 50(3), 254-263. https://doi.org/10.1177/0004867415577979

  44. Korpela, H., Miettunen, J., Rautio, N., Isohanni, M., Järvelin, M. R., Jääskeläinen,E., Auvinen, J., Keinänen-Kiukaanniemi, S., Nordström, T., & Seppälä, J.(2020). Early environmental factors and somatic comorbidity in schizophreniaand nonschizophrenic psychoses: A 50-year follow-up of the Northern FinlandBirth Cohort 1966. European Psychiatry, 63(1), e24. https://doi.org/10.1192/j.eurpsy.2020.25

  45. Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2009).Prevalence of alcohol use disorders in schizophrenia--a systematic reviewand meta-analysis. Acta Psychiatrica Scandinavica, 120(2), 85-96. https://doi.org/10.1111/j.1600-0447.2009.01385.x

  46. Kowalski, K., & Misiak, B. (2023). Schizophrenia and the COVID-19 pandemic:A narrative review from the biomedical perspective. Revista de Psiquiatría ySalud Mental, S1888-9891(23), 00015-0. Advance online publication. https://doi.org/10.1016/j.rpsm.2023.04.002

  47. Kugathasan, P., Laursen, T. M., Grøntved, S., Jensen, S. E., Aagaard, J., & Nielsen,R. E. (2018). Increased long-term mortality after myocardial infarction inpatients with schizophrenia. Schizophrenia Research, 199, 103-108. https://doi.org/10.1016/j.schres.2018.03.015

  48. Kugathasan, P., Stubbs, B., Aagaard, J., Jensen, S. E., Munk Laursen, T., & Nielsen,R. E. (2019). Increased mortality from somatic multimorbidity in patientswith schizophrenia: a Danish nationwide cohort study. Acta PsychiatricaScandinavica, 140(4), 340-348. https://doi.org/10.1111/acps.13076

  49. Kurdyak, P., Vigod, S., Duchen, R., Jacob, B., Stukel, T., & Kiran, T. (2017). Diabetesquality of care and outcomes: Comparison of individuals with and withoutschizophrenia. General Hospital Psychiatry, 46, 7-13. https://doi.org/10.1016/j.genhosppsych.2017.02.001

  50. Lambert, T. J., Velakoulis, D., & Pantelis, C. (2003). Medical comorbidity inschizophrenia. The Medical Journal of Australia, 178(S9), S67-S70. https://doi.org/10.5694/j.1326-5377.2003.tb05311.x

  51. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D.,& Bor, D. H. (2000). Smoking and mental illness: A population-basedprevalence study. JAMA, 284(20), 2606-2610. https://doi.org/10.1001/jama.284.20.2606

  52. Laursen, T. M., Munk-Olsen, T., & Gasse, C. (2011). Chronic somatic comorbidityand excess mortality due to natural causes in persons with schizophrenia orbipolar affective disorder. PloS One, 6(9), e24597. https://doi.org/10.1371/journal.pone.0024597

  53. Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014). Excess early mortality inschizophrenia. Annual Review of Clinical Psychology, 10, 425-448. https://doi.org/10.1146/annurev-clinpsy-032813-153657

  54. Laursen, T. M., Plana-Ripoll, O., Andersen, P. K., McGrath, J. J., Toender, A., Nordentoft,M., Canudas-Romo, V., & Erlangsen, A. (2019). Cause-specific life years lost amongpersons diagnosed with schizophrenia: Is it getting better or worse? SchizophreniaResearch, 206, 284-290. https://doi.org/10.1016/j.schres.2018.11.003

  55. Lee, E. E., Liu, J., Tu, X., Palmer, B. W., Eyler, L. T., & Jeste, D. V. (2018). A wideninglongevity gap between people with schizophrenia and general population: Aliterature review and call for action. Schizophrenia Research, 196, 9-13. https://doi.org/10.1016/j.schres.2017.09.005

  56. Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007). Physical illnessand schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica,116(5), 317-333. https://doi.org/10.1111/j.1600-0447.2007.01095.x

  57. Lin, G. M., Chen, Y. J., Kuo, D. J., Jaiteh, L. E., Wu, Y. C., Lo, T. S., & Li, Y. H.(2013). Cancer incidence in patients with schizophrenia or bipolar disorder:anationwide population-based study in Taiwan, 1997-2009. SchizophreniaBulletin, 39(2), 407-416. https://doi.org/10.1093/schbul/sbr162

  58. Lu, M. L. R., De Venecia, T. A., Goyal, A., Rodriguez Ziccardi, M., Kanjanahattakij,N., Shah, M. K., Davila, C. D, & Figueredo, V. M. (2017). Psychiatricconditions as predictors of rehospitalization among African American patientshospitalized with heart failure. Clinical Cardiology, 40(11), 1020-1025. https://doi.org/10.1002/clc.22760

  59. Martens, P. J., Chochinov, H. M., Prior, H. J., Fransoo, R., Burland, E., & Need toKnow Team. (2009). Are cervical cancer screening rates different for womenwith schizophrenia? A Manitoba population-based study. SchizophreniaResearch, 113(1), 101-106. https://doi.org/10.1016/j.schres.2009.04.015

  60. Martinez-Nicolas, I., Basaraba, C., Delgado-Gomez, D., Lopez-Fernandez, O., Baca-Garcia, E., Wainberg, M. L. (2023b). The Electronic Mental Wellness Tool asa Self-Administered Brief Screening Instrument for Mental Disorders in theGeneral Spanish Population during the Post-COVID-19 Era. InternationalJournal of Environmental Research and Public Health, 20(4), 3204. https://doi.org/10.3390/ijerph20043204

  61. Martínez-Nicolás, I., Molina-Pizarro, C.A., Franco, A.R., Arenas Castañeda, P. E.,Maya, C., Barahona, I., Martínez-Alés, G., Aroca Bisquert, F., Delgado-Gomez,D., Dervic, K., Lopez-Fernandez, O., Baca-García, E., & Barrigón, M. L.(2023a). What seems to explain suicidality in Yucatan Mexican young adults?Findings from an app-based mental health screening test using the SMARTSCREENprotocol. Current Psychology, 42(35), 30767-30779). https://doi.org/10.1007/s12144-022-03686-8

  62. McGinty, E. E., Baller, J., Azrin, S. T., Juliano-Bult, D., & Daumit, G. L. (2015).Quality of medical care for persons with serious mental illness: A comprehensivereview. Schizophrenia Research, 165(2-3), 227-235. https://doi.org/10.1016/j.schres.2015.04.010

  63. McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: a conciseoverview of incidence, prevalence, and mortality. Epidemiologic Reviews, 30,67-76. https://doi.org/10.1093/epirev/mxn001

  64. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group. (2009).Preferred reporting items for systematic reviews and meta-analyses: thePRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097

  65. Nielsen, P. R., Laursen, T. M., & Agerbo, E. (2016). Comorbidity of schizophrenia andinfection: a population-based cohort study. Social Psychiatry and PsychiatricEpidemiology, 51(12), 1581-1589. https://doi.org/10.1007/s00127-016-1297-1

  66. Nordentoft, M., Plana-Ripoll, O., & Laursen, T. M. (2021). Cancer and schizophrenia.Current Opinion in Psychiatry, 34(3), 260-265. https://doi.org/10.1097/YCO.0000000000000697

  67. Oud, M. J., & Meyboom-de Jong, B. (2009). Somatic diseases in patients withschizophrenia in general practice: their prevalence and health care. BMC FamilyPractice, 10, 32. https://doi.org/10.1186/1471-2296-10-32

  68. Oud, M. J., Schuling, J., Groenier, K. H., Verhaak, P. F., Slooff, C. J., Dekker, J. H., &Meyboom-de Jong, B. (2010). Care provided by general practitioners to patientswith psychotic disorders: a cohort study. BMC Family Practice, 11, 92. https://doi.org/10.1186/1471-2296-11-92

  69. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C.D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville,J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement:an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71

  70. Pankiewicz-Dulacz, M., Stenager, E., Chen, M., & Stenager, E. N. (2019). Riskfactors of major infections in schizophrenia. A nationwide Danish register study.Journal of Psychosomatic Research, 121, 60-67. https://doi.org/10.1016/j.jpsychores.2019.04.003

  71. Partti, K., Vasankari, T., Kanervisto, M., Perälä, J., Saarni, S. I., Jousilahti, P.,Lönnqvist, J., & Suvisaari, J. (2015). Lung function and respiratory diseasesin people with psychosis: population-based study. The British Journal ofPsychiatry, 207(1), 37-45. https://doi.org/10.1192/bjp.bp.113.141937

  72. Poirier, M. F., Canceil, O., Baylé, F., Millet, B., Bourdel, M. C., Moatti, C., Olié,J. P., & Attar Lévy, D. (2002). Prevalence of smoking in psychiatric patients.Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26(3), 529-537. https://doi.org/10.1016/s0278-5846(01)00304-9

  73. Polcwiartek, C., Kragholm, K., Rohde, C., Hashemi, N., Vang, T., & Nielsen, J.(2017). Diabetic ketoacidosis and diabetes associated with antipsychoticexposure among a previously diabetes-naive population with schizophrenia: anationwide nested case-control study. Diabetologia, 60(9), 1678-1690. https://doi.org/10.1007/s00125-017-4320-5

  74. Porras-Segovia, A., Krivoy, A., Horowitz, M., Thomas, G., Bolstridge, M., Ion, D.,& Shergill, S. S. (2017). Rapid-onset clozapine-induced loss of glycaemiccontrol: case report. BJPsych Open, 3(3), 138-140. https://doi.org/10.1192/bjpo.bp.117.004481

  75. Räsänen, S., Hakko, H., Viilo, K., Meyer-Rochow, V. B., & Moring, J. (2003).Excess mortality among long-stay psychiatric patients in Northern Finland.Social Psychiatry and Psychiatric Epidemiology, 38(6), 297-304. https://doi.org/10.1007/s00127-003-0635-2

  76. Razzano, L. A., Cook, J. A., Yost, C., Jonikas, J. A., Swarbrick, M. A., Carter, T. M.,& Santos, A. (2015). Factors associated with co-occurring medical conditionsamong adults with serious mental disorders. Schizophrenia Research, 161(2-3),458-464. https://doi.org/10.1016/j.schres.2014.11.021

  77. Rodrigues, M., Wiener, J. C., Stranges, S., Ryan, B. L., & Anderson, K. K. (2021).The risk of physical multimorbidity in people with psychotic disorders: Asystematic review and meta-analysis. Journal of Psychosomatic Research, 140,110315. https://doi.org/10.1016/j.jpsychores.2020.110315

  78. Salokangas, R. K. (2007). Medical problems in schizophrenia patients living in thecommunity (alternative facilities). Current Opinion in Psychiatry, 20(4), 402-405. https://doi.org/10.1097/YCO.0b013e328122d99b

  79. Schoepf, D., Potluri, R., Uppal, H., Natalwala, A., Narendran, P., & Heun, R. (2012).Type-2 diabetes mellitus in schizophrenia: increased prevalence and majorrisk factor of excess mortality in a naturalistic 7-year follow-up. EuropeanPsychiatry, 27(1), 33-42. https://doi.org/10.1016/j.eurpsy.2011.02.009

  80. Schoepf, D., Uppal, H., Potluri, R., & Heun, R. (2014). Physical comorbidity andits relevance on mortality in schizophrenia: a naturalistic 12-year follow-upin general hospital admissions. European Archives of Psychiatry and ClinicalNeuroscience, 264(1), 3-28. https://doi.org/10.1007/s00406-013-0436-x

  81. Schulman-Marcus, J., Goyal, P., Swaminathan, R. V., Feldman, D. N., Wong, S. C.,Singh, H. S., Minutello, R. M., Bergman, G., & Kim, L. K. (2016). Comparisonof Trends in Incidence, Revascularization, and In-Hospital Mortality in STElevationMyocardial Infarction in Patients with Versus Without Severe MentalIllness. The American Journal of Cardiology, 117(9), 1405-1410. https://doi.org/10.1016/j.amjcard.2016.02.006

  82. Shen, H. N., Lu, C. L., & Yang, H. H. (2011). Increased risks of acute organdysfunction and mortality in intensive care unit patients with schizophrenia: anationwide population-based study. Psychosomatic Medicine, 73(7), 620-626.https://doi.org/10.1097/PSY.0b013e3182280016

  83. 83 Sohn, M., Moga, D. C., & Talbert, J. (2015). Mental disorder comorbidity and inhospitalmortality among patients with acute myocardial infarction. GeriatricMental Health Care, 3(1), 7-11. https://doi.org/10.1016/j.gmhc.2015.04.002

  84. Soontornniyomkij, V., Lee, E. E., Jin, H., Martin, A. S., Daly, R. E., Liu, J., Tu, X.M., Eyler, L. T., & Jeste, D. V. (2019). Clinical Correlates of Insulin Resistancein Chronic Schizophrenia: Relationship to Negative Symptoms. Frontiers inPsychiatry, 10, 251. https://doi.org/10.3389/fpsyt.2019.00251

  85. Sørensen, H. J., Nielsen, P. R., Benros, M. E., Pedersen, C. B., & Mortensen,P. B. (2015). Somatic diseases and conditions before the first diagnosis ofschizophrenia: a nationwide population-based cohort study in more than900 000 individuals. Schizophrenia Bulletin, 41(2), 513-521. https://doi.org/10.1093/schbul/sbu110

  86. Spilsbury, K., Rosenwax, L., Brameld, K., Kelly, B., & Arendts, G. (2018). Morbidityburden and community-based palliative care are associated with rates of hospitaluse by people with schizophrenia in the last year of life: A population-basedmatched cohort study. PloS One, 13(11), e0208220. https://doi.org/10.1371/journal.pone.0208220

  87. Stahl, S. M., Mignon, L., & Meyer, J. M. (2009). Which comes first: atypicalantipsychotic treatment or cardiometabolic risk? Acta Psychiatrica Scandinavica,119(3), 171-179. https://doi.org/10.1111/j.1600-0447.2008.01334.x

  88. Tanskanen, A., Tiihonen, J., & Taipale, H. (2018). Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatrica Scandinavica, 138(6), 492-499. https://doi.org/10.1111/acps.12913

  89. Tokuda, Y., Obara, H., Nakazato, N., & Stein, G. H. (2008). Acute care hospitalmortality of schizophrenic patients. Journal of Hospital Medicine, 3(2), 110-116. https://doi.org/10.1002/jhm.256

  90. Torous, J., Firth, J., Mueller, N., Onnela, J. P., & Baker, J. T. (2017). Methodologyand Reporting of Mobile Heath and Smartphone Application Studies forSchizophrenia. Harvard Review of Psychiatry, 25(3), 146-154. https://doi.org/10.1097/HRP.0000000000000133

  91. Urrútia, G., & Bonfill, X. (2010). Declaración PRISMA: una propuesta para mejorarla publicación de revisiones sistemáticas y metaanálisis [PRISMA declaration: aproposal to improve the publication of systematic reviews and meta-analyses].Medicina Clínica, 135(11), 507-511. https://doi.org/10.1016/j.medcli.2010.01.015

  92. Vancampfort, D., Firth, J., Schuch, F. B., Rosenbaum, S., Mugisha, J., Hallgren,M., Probst, M., Ward, P. B., Gaughran, F., De Hert, M., Carvalho, A. F., &Stubbs, B. (2017). Sedentary behavior and physical activity levels in peoplewith schizophrenia, bipolar disorder and major depressive disorder: a globalsystematic review and meta-analysis. World Psychiatry, 16(3), 308-315. https://doi.org/10.1002/wps.20458




2020     |     www.medigraphic.com